BR112017020739A2 - derivados fundidos tricíclicos de 1-cicloalquil piridin-2-ona útil para o tratamento de câncer - Google Patents
derivados fundidos tricíclicos de 1-cicloalquil piridin-2-ona útil para o tratamento de câncerInfo
- Publication number
- BR112017020739A2 BR112017020739A2 BR112017020739-7A BR112017020739A BR112017020739A2 BR 112017020739 A2 BR112017020739 A2 BR 112017020739A2 BR 112017020739 A BR112017020739 A BR 112017020739A BR 112017020739 A2 BR112017020739 A2 BR 112017020739A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyclicalkyl
- pyridin
- cancer treatment
- derivatives useful
- tricyclic fused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1636/CHE/2015 | 2015-03-30 | ||
| IN1636CH2015 | 2015-03-30 | ||
| PCT/IN2016/050098 WO2016157221A1 (en) | 2015-03-30 | 2016-03-30 | Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017020739A2 true BR112017020739A2 (pt) | 2018-07-17 |
| BR112017020739B1 BR112017020739B1 (pt) | 2023-03-14 |
Family
ID=56015058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020739-7A BR112017020739B1 (pt) | 2015-03-30 | 2016-03-30 | Compostos fundidos tricíclicos de 1-cicloalquil piridin-2-ona, composição farmacêutica e seus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10689390B2 (pt) |
| EP (1) | EP3277683B1 (pt) |
| JP (1) | JP6764877B2 (pt) |
| KR (1) | KR102588109B1 (pt) |
| CN (1) | CN107548393B (pt) |
| AU (1) | AU2016242473B2 (pt) |
| BR (1) | BR112017020739B1 (pt) |
| CA (1) | CA2980266A1 (pt) |
| DK (1) | DK3277683T3 (pt) |
| ES (1) | ES2911886T3 (pt) |
| HK (1) | HK1248686A1 (pt) |
| IL (1) | IL254528B (pt) |
| MX (1) | MX2017012387A (pt) |
| PL (1) | PL3277683T3 (pt) |
| PT (1) | PT3277683T (pt) |
| RU (1) | RU2721120C2 (pt) |
| WO (1) | WO2016157221A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2734959C2 (ru) | 2015-09-09 | 2020-10-26 | Джубилант Байосис Лимитед | Трициклические конденсированные производные пиридин-2-она и их применение в качестве ингибиторов brd4 |
| EP3539960A4 (en) * | 2016-11-10 | 2020-03-18 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | NITROGEN MACROCYCLIC COMPOUND, ITS PREPARATION METHOD, ITS PHARMACEUTICAL COMPOSITION AND ITS APPLICATION |
| CN111819181A (zh) * | 2018-05-10 | 2020-10-23 | 罗欣药业(上海)有限公司 | 苯并七元杂环类化合物、其制备方法、药物组合物及应用 |
| CN110172068A (zh) * | 2019-06-05 | 2019-08-27 | 河南龙湖生物技术有限公司 | 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1545767A (en) * | 1976-06-30 | 1979-05-16 | Aspro Nicholas Ltd | Isoquinoline derivatives |
| TW200904403A (en) | 2007-04-25 | 2009-02-01 | Daiichi Sankyo Co Ltd | Tricyclic aryl compounds |
| EP2276767B1 (en) | 2008-03-31 | 2014-05-07 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| JP5844358B2 (ja) * | 2010-06-22 | 2016-01-13 | グラクソスミスクライン エルエルシー | ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤 |
| AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| KR20150119926A (ko) * | 2013-02-19 | 2015-10-26 | 바이엘 파마 악티엔게젤샤프트 | 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀 |
| US10035800B2 (en) * | 2013-03-12 | 2018-07-31 | Abbvie Inc. | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors |
| WO2015018520A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| US9814728B2 (en) | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
-
2016
- 2016-03-30 PT PT167235365T patent/PT3277683T/pt unknown
- 2016-03-30 DK DK16723536.5T patent/DK3277683T3/da active
- 2016-03-30 PL PL16723536T patent/PL3277683T3/pl unknown
- 2016-03-30 CN CN201680020269.3A patent/CN107548393B/zh active Active
- 2016-03-30 KR KR1020177031273A patent/KR102588109B1/ko active IP Right Grant
- 2016-03-30 MX MX2017012387A patent/MX2017012387A/es active IP Right Grant
- 2016-03-30 US US15/562,381 patent/US10689390B2/en active Active
- 2016-03-30 CA CA2980266A patent/CA2980266A1/en active Pending
- 2016-03-30 EP EP16723536.5A patent/EP3277683B1/en active Active
- 2016-03-30 RU RU2017135205A patent/RU2721120C2/ru active
- 2016-03-30 BR BR112017020739-7A patent/BR112017020739B1/pt active IP Right Grant
- 2016-03-30 ES ES16723536T patent/ES2911886T3/es active Active
- 2016-03-30 JP JP2017551712A patent/JP6764877B2/ja active Active
- 2016-03-30 AU AU2016242473A patent/AU2016242473B2/en active Active
- 2016-03-30 WO PCT/IN2016/050098 patent/WO2016157221A1/en active Application Filing
-
2017
- 2017-09-17 IL IL254528A patent/IL254528B/en active IP Right Grant
-
2018
- 2018-06-26 HK HK18108222.3A patent/HK1248686A1/zh unknown
-
2020
- 2020-05-07 US US16/869,517 patent/US11319326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2980266A1 (en) | 2016-10-06 |
| PL3277683T3 (pl) | 2022-05-23 |
| WO2016157221A1 (en) | 2016-10-06 |
| EP3277683B1 (en) | 2022-03-09 |
| KR102588109B1 (ko) | 2023-10-12 |
| US11319326B2 (en) | 2022-05-03 |
| RU2017135205A (ru) | 2019-04-10 |
| JP2018510203A (ja) | 2018-04-12 |
| US20180282345A1 (en) | 2018-10-04 |
| US20200331926A1 (en) | 2020-10-22 |
| AU2016242473B2 (en) | 2020-06-25 |
| MX2017012387A (es) | 2018-06-11 |
| ES2911886T3 (es) | 2022-05-23 |
| KR20170132278A (ko) | 2017-12-01 |
| RU2721120C2 (ru) | 2020-05-15 |
| RU2017135205A3 (pt) | 2019-07-17 |
| BR112017020739B1 (pt) | 2023-03-14 |
| EP3277683A1 (en) | 2018-02-07 |
| IL254528A0 (en) | 2017-11-30 |
| DK3277683T3 (en) | 2022-05-02 |
| JP6764877B2 (ja) | 2020-10-07 |
| US10689390B2 (en) | 2020-06-23 |
| HK1248686A1 (zh) | 2018-10-19 |
| PT3277683T (pt) | 2022-06-28 |
| IL254528B (en) | 2020-11-30 |
| CN107548393B (zh) | 2021-03-02 |
| CN107548393A (zh) | 2018-01-05 |
| AU2016242473A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1262819A1 (zh) | 提供光療的設備 | |
| IL261885A (en) | Pyrazolopyrimidine history | |
| BR112017008399A2 (pt) | abordagem de imunoterapia de combinação para tratamento de câncer | |
| IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| DK3286188T3 (da) | Isoxazolyl-substituerede imidazopyridiner | |
| IL259996A (en) | Combinations for cancer treatment | |
| KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| IL259864A (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| HK1250942A1 (zh) | 用於治療癌症的方法 | |
| MA41790A (fr) | Dérivé de morphinane | |
| HK1250943A1 (zh) | 用於治療癌症的方法 | |
| BR112017020739A2 (pt) | derivados fundidos tricíclicos de 1-cicloalquil piridin-2-ona útil para o tratamento de câncer | |
| CL2014002313S1 (es) | Aparato de iluminacion | |
| BR112016027819A2 (pt) | Processo de preparação de derivados de tiazole | |
| IL247808A (en) | History of splosporin for the treatment of cancer | |
| ES2697898T8 (es) | Compuestos triazólicos tricíclicos | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 | |
| DK3277325T3 (da) | Kombinationsimmunterapi for cancer | |
| HK1259615A1 (zh) | 谷氨酸-高z元素化合物治療癌症 | |
| PT3319956T (pt) | Derivados de oxopiridina substituída | |
| BR112018000209A2 (pt) | derivados de oxopiridina sibstituída |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2016, OBSERVADAS AS CONDICOES LEGAIS |